LivaNova PLC
NASDAQ:LIVN

Watchlist Manager
LivaNova PLC Logo
LivaNova PLC
NASDAQ:LIVN
Watchlist
Price: 51.32 USD -0.74% Market Closed
Market Cap: 2.8B USD
Have any thoughts about
LivaNova PLC?
Write Note

LivaNova PLC
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LivaNova PLC
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
LivaNova PLC
NASDAQ:LIVN
Gross Profit
$841.7m
CAGR 3-Years
9%
CAGR 5-Years
2%
CAGR 10-Years
12%
Smith & Nephew PLC
LSE:SN
Gross Profit
$3.9B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
N/A
EKF Diagnostics Holdings PLC
LSE:EKF
Gross Profit
ÂŁ24.5m
CAGR 3-Years
-16%
CAGR 5-Years
1%
CAGR 10-Years
4%
Angle PLC
LSE:AGL
Gross Profit
ÂŁ1.4m
CAGR 3-Years
30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Gross Profit
ÂŁ15m
CAGR 3-Years
14%
CAGR 5-Years
404%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Gross Profit
-$961.9k
CAGR 3-Years
N/A
CAGR 5-Years
-165%
CAGR 10-Years
N/A
No Stocks Found

LivaNova PLC
Glance View

Market Cap
2.8B USD
Industry
Health Care

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The firm operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

LIVN Intrinsic Value
81.64 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is LivaNova PLC's Gross Profit?
Gross Profit
841.7m USD

Based on the financial report for Sep 30, 2024, LivaNova PLC's Gross Profit amounts to 841.7m USD.

What is LivaNova PLC's Gross Profit growth rate?
Gross Profit CAGR 10Y
12%

Over the last year, the Gross Profit growth was 10%. The average annual Gross Profit growth rates for LivaNova PLC have been 9% over the past three years , 2% over the past five years , and 12% over the past ten years .

Back to Top